Clinical trials: PET/CT
Prostate Cancer (Diagnosis), ACP3
68Ga-XMFH01 PET/Fluorescence Imaging in Prostate Cancer
This study aims to evaluate the feasibility, safety, and diagnostic performance of 68Ga-XMFH01, a novel ACP3-targeted dual-modality PET and fluorescence imaging probe, for preoperative PET/CT imaging and intraoperative…
- Conditions
- Prostate Cancer (Diagnosis), ACP3, PET / CT
- Trial name
- NCT07885423
- Testing
- 68Ga-XMFH01 PET/CT
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Solid Tumor (Excluding CNS), HER2
68Ga-XHER2 PET/CT for HER2 Assessment
The objective of this study is to evaluate the feasibility of 68Ga-XHER2 PET/CT as a noninvasive imaging approach for assessing HER2 expression in patients with solid tumors and to investigate the correlation between tracer…
- Conditions
- Solid Tumor (Excluding CNS), HER2, PET / CT
- Trial name
- NCT07885436
- Testing
- 68Ga-XHER2 PET/CT
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xiamen University
PET/CT
Positron Emission Tomography/Computed Tomography (PECT/CT) Double-Scanning Study
This study aims to collect clinical image data using the Omni 128 cm PET/CT system and compare image quality and performance with clinically indicated PET/CT examinations.
- Trial name
- NCT07857161
- Testing
- Omni 128cm PET/CT
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Prostate Cancer, PSMA PET/CT
Brief Title: INTROSPECT: Intraoperative PSMA PET/CT Imaging During Radical Prostatectomy
During prostate cancer surgery, the surgeon aims to remove the tumor completely while preserving the surrounding tissue responsible for urinary continence and sexual potency.
- Conditions
- Prostate Cancer, PSMA PET/CT, Margin Assessment
- Trial name
- INTROSPECT (NCT07829068)
- Testing
- study-specific administration of 68Ga-PSMA-11 followed by ex vivo PET/CT imaging of the prostatectomy specimen
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University Hospital, Geneva
DLL3-expressing Tumors, PET / CT
DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.
- Conditions
- DLL3-expressing Tumors, PET / CT, Neuroendocrine Cancer
- Trial name
- NCT07458906
- Testing
- Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Pilot Study, PET/CT Imaging
A Pilot Study to Correlate 4-18F- Fluoro-1-naphthol 18F-4FN PET/CT Imaging With Graft Versus Host Disease Manifestations
To study the safety and possible side effects of using the imaging agent 4-[18F]Fluoro-1-Naphthol (also called [18F]4FN) in PET/CT scans for participants with chronic GVHD.
- Conditions
- Pilot Study, PET/CT Imaging, Host Disease Manifestation
- Trial name
- NCT07325253
- Testing
- [18F]-4FN, PET-CT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma (HCC), Glypican-3
GPC3-Targeted PET/CT in Hepatocellular Carcinoma
The objective of the study is to evaluate the diagnostic value of GPC3-targeted PET/CT in patients with suspected or histologically/clinically confirmed hepatocellular carcinoma, and to compare with contrast-enhanced MRI.
- Conditions
- Hepatocellular Carcinoma (HCC), Glypican-3, GPC3-targeted PET/CT
- Trial name
- NCT07677774
- Testing
- GPC3-targeted PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Nasopharyngeal Carcinoma (NPC), PET / CT
Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma
This is an observational cohort study designed to (1) evaluate whether Gallium-68 (68Ga)-labeled fibroblast activation protein inhibitor ligand LM3 (68Ga-FAPI-LM3) positron emission tomography/computed tomography (PET/CT)…
- Trial name
- NCT07137052
- Where
- China
- Volunteers
- 732 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Head and Neck Squamous Cell Carcinoma, PET/CT
PET/CT Follow up for Head and Neck Squamous Cell Carcinoma
PET/CT follow up for Head and Neck Squamous Cell Carcinoma The following is a presentation of a prospective protocol, named PET/CT follow up for Head and Neck Squamous Cell Carcinoma (PET Follow), including patients who have…
- Trial name
- PET Follow (NCT05707078)
- Testing
- Neck dissection
- Where
- Denmark
- Volunteers
- 600 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
PET-CT
Performance of Amino Acid Positons Emission Tomography in Brain Metastases
Differentiating radiation necrosis from tumor progression in patients with brain metastases has a major therapeutic and prognostic implications
- Trial name
- DYNAMET (NCT07676448)
- Testing
- PET exam analysis
- Volunteers
- 80 people
- Sponsor
- Central Hospital, Nancy, France
Triple Negative Breast Cancer, Immune Checkpoint Inhibitor
Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
This study plans to enroll 30 patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who are scheduled to receive at least two cycles of a regimen containing an immune checkpoint inhibitor (ICI).
- Conditions
- Triple Negative Breast Cancer, Immune Checkpoint Inhibitor, Granzyme B PET/CT
- Trial name
- NCT07705438
- Testing
- [68Ga]Ga-DOTA-GSI PET/CT (Granzyme B PET/CT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
NSCLC, EGFR Activating Mutation
Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC
The primary objective is to evaluate the correlation between ⁶⁸Ga-MY6349 PET/CT-derived metrics reflecting tumoral TROP2 expression activity (including SUVmax, SUVmean, MTV, TLG, etc.) and progression-free survival (PFS) assessed…
- Conditions
- NSCLC, EGFR Activating Mutation, EGFR-TKI-resistant Non-Small Cell Lung Cancer, Trop2
- Trial name
- NCT07685197
- Testing
- receive treatment with TROP2-targeted ADC and targeted molecular PET/CT imaging using ⁶⁸Ga-MY6349 injection
- Volunteers
- 100 people
- Sponsor
- Zhou Chengzhi
PET/CT, Small Cell Lung Cancer ( SCLC )
DLL3-Targeted PET/CT in Small Cell Lung Cancer
The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed small cell lung cancer, and to compare with conventional imaging modalities.
- Conditions
- PET/CT, Small Cell Lung Cancer ( SCLC ), DLL3-targeted PET/CT, Delta-like Protein 3
- Trial name
- NCT07677787
- Testing
- conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Brown Adipose Tissue, Cold Exposure
Intermittent Cold Exposure and Brown Adipose Tissue Hyperplasia
This clinical trial explores how repeated short-term cold exposure impacts the molecular and physiological function of brown adipose tissue (BAT), a thermogenic organ associated with improved cardiometabolic health.
- Conditions
- Brown Adipose Tissue, Cold Exposure, 18F-FDG PET/CT
- Trial name
- ICEBATH (NCT07048405)
- Testing
- Cooling, Biopsies, Injection of 18F-FDG
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Prostate Cancer, Gleason Score
Dual-tracer PET Radiomics for Prostate Cancer Stratification
This single-center retrospective study aims to develop an interpretable radiomics model based on dual-tracer PET/CT to preoperatively predict the postoperative pathological Gleason grade group in treatment-naïve prostate cancer…
- Conditions
- Prostate Cancer, Gleason Score, PET/CT, Radiomics
- Trial name
- NCT07655648
- Testing
- PET/CT with Gallium-68 labeled PSMA and RM26
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xiangya Hospital of Central South University
Short-Term Renal-Hematologic Safety, Contrast-Enhanced MRI and FDG-PET/CT
Comparative Evaluation of Contrast-Enhanced MRI and FDG-PET/CT in Spinal Pathology: Image Quality and Short-Term Renal-Hematologic Safety
This prospective comparative observational study evaluates image quality characteristics and short-term physiological effects associated with contrast-enhanced magnetic resonance imaging (MRI) and fluorodeoxyglucose positron…
- Conditions
- Short-Term Renal-Hematologic Safety, Contrast-Enhanced MRI and FDG-PET/CT, Spinal Pathology
- Trial name
- NCT07640386
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Cairo University
Patients Undergoing PET/CT Investigation or Nuclear Medicine Therapy
New AI-based Technologies in Nuclear Medicine
The study aims to identify and predict radiopharmaceutical extravasation events using new semi-quantitative parameters and machine learning models. It involves dose rate measurements to develop metrics for real-time monitoring.
- Trial name
- AI-basedMedNuc (NCT07174089)
- Testing
- RadEye SPRD-ER device: spectrometric radiation detector capable of detecting gamma radiation.
- Where
- Italy
- Volunteers
- 1,500 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Prostate Cancer, Molecular Imaging
Molecular Profiling of MRI-PSMA PET Discordance in Prostate Cancer
MRI and PSMA-PET are highly sensitive imaging tools for prostate cancer, yet they often detect different lesions. These discordant findings pose clinical uncertainty because their biological significance is unclear.
- Conditions
- Prostate Cancer, Molecular Imaging, Transcriptomics, RNA
- Trial name
- MP-PET-MRI (NCT07485257)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS San Raffaele
Non-Small Cell Lung Cancer, Malignant Neoplasm
Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
Lung malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment.
- Conditions
- Non-Small Cell Lung Cancer, Malignant Neoplasm, Pulmonary Nodules, PET/CT
- Trial name
- NCT07487883
- Testing
- PET/CT scans
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University People's Hospital
Non-Small Cell Lung Cancer, PET/CT
FAP-targeted PET/NIR in Lung Malignant Tumors
Single center, prospective, diagnostic study. Patients with stage II-IIIB resectable NSCLC diagnosed by pathology were included.
- Conditions
- Non-Small Cell Lung Cancer, PET/CT, Neoadjuvant Therapy
- Trial name
- NCT07498933
- Testing
- PET/CT scans
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital